Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SARAH E LAND

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1700956406
CMS profile
32047
Location
TULSA, OK

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$36,295.44

281 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 6; records 51–100 of 281 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SARAH E LAND

NPI 1700956406 · CMS profile ID 32047

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

TULSA, OK

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 6; records 51–100 of 281 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1700956406?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SARAH E LAND, NPI 1700956406, CMS profile ID 32047. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 281 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1700956406?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). SARAH E LAND, NPI 1700956406, CMS profile ID 32047. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 281 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1700956406?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
SARAH E LAND, NPI 1700956406, CMS profile ID 32047, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 6; records 51–100 of 281 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1700956406?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

281 matching records · $36,295.44 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 281 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 281.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Teva Pharmaceuticals USA, Inc. $14.8211/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839628465 CMS
Ironshore Pharmaceuticals Inc. $5.5610/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 840365051 CMS
Takeda Pharmaceuticals U.S.A., Inc. $17.1410/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820036975 CMS
AbbVie Inc. $14.6210/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795217099 CMS
Sunovion Pharmaceuticals Inc. $14.9010/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821820735 CMS
AbbVie Inc. $3.2510/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795217083 CMS
AbbVie Inc. $2,200.0010/26/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795217087 CMS
AbbVie Inc. $57.5510/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795217093 CMS
Janssen Pharmaceuticals, Inc $19.4610/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788591191 CMS
JAZZ PHARMACEUTICALS INC. $17.9210/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845563253 CMS
Sunovion Pharmaceuticals Inc. $15.0410/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821817372 CMS
Alkermes, Inc. $21.5310/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818261011 CMS
Corium, Inc. $6.4310/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 775553895 CMS
Lundbeck LLC $7.1810/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845919097 CMS
Eisai Inc. $14.4510/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818027792 CMS
Ironshore Pharmaceuticals Inc. $5.6810/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 840365043 CMS
AbbVie Inc. $4.8310/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795217071 CMS
AbbVie Inc. $1,760.0010/18/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795217077 CMS
Ironshore Pharmaceuticals Inc. $20.2210/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 840365011 CMS
Otsuka America Pharmaceutical, Inc. $16.7110/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834746497 CMS
Sunovion Pharmaceuticals Inc. $16.2110/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821780685 CMS
AbbVie Inc. $12.7910/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795217065 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2.8510/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820036971 CMS
ITI, Inc. $13.1110/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830151495 CMS
Sunovion Pharmaceuticals Inc. $14.4110/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821830925 CMS
AbbVie Inc. $10.6110/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795217059 CMS
Neurocrine Biosciences, Inc. $11.4010/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837801329 CMS
Corium, Inc. $8.1910/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 775552773 CMS
Janssen Pharmaceuticals, Inc $11.0510/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788591149 CMS
Sunovion Pharmaceuticals Inc. $15.7609/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821795283 CMS
AbbVie Inc. $13.0609/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795217053 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2.7809/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820036967 CMS
Eisai Inc. $13.8809/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818007343 CMS
Ironshore Pharmaceuticals Inc. $5.5309/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 840364992 CMS
Ironshore Pharmaceuticals Inc. $9.8909/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 840364973 CMS
JAZZ PHARMACEUTICALS INC. $19.5709/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845559033 CMS
Sunovion Pharmaceuticals Inc. $15.2909/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821810961 CMS
Lundbeck LLC $18.8809/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845919095 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2.7109/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820036963 CMS
AbbVie Inc. $11.8909/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795217047 CMS
Sunovion Pharmaceuticals Inc. $21.0509/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821626615 CMS
AbbVie Inc. $11.3309/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795217041 CMS
Adlon Therapeutics L.P. $14.7309/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 844837157 CMS
Otsuka America Pharmaceutical, Inc. $9.6409/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834746495 CMS
Teva Pharmaceuticals USA, Inc. $11.3609/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839628461 CMS
Corium, Inc. $8.2909/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 775551825 CMS
Takeda Pharmaceuticals U.S.A., Inc. $13.9609/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820036959 CMS
Ironshore Pharmaceuticals Inc. $9.8909/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 840365169 CMS
Sunovion Pharmaceuticals Inc. $18.1809/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821715435 CMS
Takeda Pharmaceuticals U.S.A., Inc. $17.9909/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820036955 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,448.55 193
PY2020 $5,883.71 158
PY2021 $36,295.44 281
PY2022 $30,816.83 227
PY2023 $49,094.22 276
PY2024 $50,174.68 238
PY2025 $112,589.38 335

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $492,567.03 31
PY2024 Recipient $4,282.00 1
PY2024 Principal investigator $808,477.67 42
PY2023 Recipient $319.50 2
PY2023 Principal investigator $683,506.81 36
PY2022 Recipient $9,278.00 1
PY2022 Principal investigator $245,311.58 21
PY2021 Principal investigator $171,491.70 38
PY2020 Recipient $2,188.42 6
PY2020 Principal investigator $98,543.66 32
PY2019 Recipient $5,905.50 8
PY2019 Principal investigator $16,869.12 5

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

31 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $250.00 12/31/2025 Non-covered Recipient Entity
CENTRAL STATES RESEARCH LLC
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine with an Open-Label Extension No dispute reported 06/30/2026 1202533555
Principal investigator 1 PFIZER INC. $1,422.75 12/25/2025 Non-covered Recipient Entity
Central States Research
A PHASE 1 MULTICENTER OPENLABEL SINGLEDOSE STUDY TO EVALUATE THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF ZAVEGEPANT IN CHILDREN 6 TO LESS THAN 12 YEARS OF AGE WITH HISTORY OF MIGRAINE No dispute reported 06/30/2026 1228738063
Principal investigator 1 Novo Nordisk AS $5,374.35 12/22/2025 Non-covered Recipient Entity
CENTRAL STATES RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1213719785
Principal investigator 1 ABBVIE INC. $9,600.00 12/04/2025 Non-covered Recipient Entity
CENTRAL STATES RESEARCH LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202528324
Principal investigator 1 Novo Nordisk AS $2,211.85 10/29/2025 Non-covered Recipient Entity
CENTRAL STATES RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1213834254
Principal investigator 1 PFIZER INC. $297.00 10/15/2025 Non-covered Recipient Entity
Central States Research
A PHASE 1 MULTICENTER OPENLABEL SINGLEDOSE STUDY TO EVALUATE THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF ZAVEGEPANT IN CHILDREN 6 TO LESS THAN 12 YEARS OF AGE WITH HISTORY OF MIGRAINE No dispute reported 06/30/2026 1228730664
Principal investigator 1 PFIZER INC. $5,699.37 09/26/2025 Non-covered Recipient Entity
Central States Research
A PHASE 1 MULTICENTER OPENLABEL SINGLEDOSE STUDY TO EVALUATE THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF ZAVEGEPANT IN CHILDREN 6 TO LESS THAN 12 YEARS OF AGE WITH HISTORY OF MIGRAINE No dispute reported 06/30/2026 1228759067
Principal investigator 1 Eli Lilly and Company $369.00 09/09/2025 Non-covered Recipient Entity
CENTRAL STATE RESEARCH
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187876639
Principal investigator 1 Novo Nordisk AS $15,592.97 07/16/2025 Non-covered Recipient Entity
CENTRAL STATES RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1213836014
Principal investigator 1 PFIZER INC. $11,037.00 06/26/2025 Non-covered Recipient Entity
Central States Research
A PHASE 1 MULTICENTER OPENLABEL SINGLEDOSE STUDY TO EVALUATE THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF ZAVEGEPANT IN CHILDREN 6 TO LESS THAN 12 YEARS OF AGE WITH HISTORY OF MIGRAINE No dispute reported 06/30/2026 1228790383
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $21,317.58 06/24/2025 Non-covered Recipient Entity
Central States Research, Llc
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Agitation Associated with Alzheimers Disease No dispute reported 06/30/2026 1235998210
Principal investigator 1 Eli Lilly and Company $5,000.00 06/23/2025 Non-covered Recipient Entity
CENTRAL STATE RESEARCH
ASSESSMENT OF SAFETY AND EFFICACY OF SUBCUTANEOUS REMTERNETUG IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187875579
Principal investigator 1 Eli Lilly and Company $3,500.00 06/23/2025 Non-covered Recipient Entity
CENTRAL STATE RESEARCH
A PHASE 2B DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF BIMAGRUMAB AND TIRZEPATIDE, ALONE OR IN COMBINATION, TO INVESTIGATE THE EFFICACY AND SAFETY IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES No dispute reported 06/30/2026 1187878915
Principal investigator 1 Eli Lilly and Company $5,000.00 06/23/2025 Non-covered Recipient Entity
CENTRAL STATE RESEARCH
ASSESSMENT OF SAFETY AND EFFICACY OF INTRAVENOUS REMTERNETUG IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1187879297
Principal investigator 1 Novo Nordisk AS $3,480.07 06/23/2025 Non-covered Recipient Entity
CENTRAL STATES RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1213743047
Principal investigator 1 Novo Nordisk AS $3,974.74 05/21/2025 Non-covered Recipient Entity
CENTRAL STATES RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1213746875
Principal investigator 1 Eli Lilly and Company $4,331.10 04/27/2025 Non-covered Recipient Entity
CENTRAL STATE RESEARCH
A PHASE 2B DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF BIMAGRUMAB AND TIRZEPATIDE, ALONE OR IN COMBINATION, TO INVESTIGATE THE EFFICACY AND SAFETY IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES No dispute reported 06/30/2026 1187879299
Principal investigator 1 Novo Nordisk AS $5,314.39 04/21/2025 Non-covered Recipient Entity
CENTRAL STATES RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1213707221
Principal investigator 1 Biogen, Inc. $2,162.00 04/16/2025 Non-covered Recipient Entity
Central States Research LLC
A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants With Alzheimer's Disease No dispute reported 06/30/2026 1236947368
Principal investigator 1 Novo Nordisk AS $3,764.92 03/28/2025 Non-covered Recipient Entity
CENTRAL STATES RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1213848335
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $75.00 03/27/2025 Non-covered Recipient Entity
CENTRAL STATES RESEARCH LLC
A LONG-TERM, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF FLEXIBLE-DOSE BREXPIPRAZOLE AS MAINTENANCE TREATMENT IN ADOLESCENT PATIENTS WITH SCHIZOPHRENIA No dispute reported 06/30/2026 1225335763
Principal investigator 1 Eli Lilly and Company $36,480.00 03/25/2025 Non-covered Recipient Entity
CENTRAL STATE RESEARCH
A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES, MODERATE OR SEVERE RENAL IMPAIRMENT WITH INADEQUATE GLYCEMIC CONTROL ON BASAL INSULIN WITH OR WITHOUT METFORMIN AND/OR SGLT2 INHIBITOR No dispute reported 06/30/2026 1187878911
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $2,700.00 03/21/2025 Non-covered Recipient Entity
CENTRAL STATES RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF AVP-786 (DEUDEXTROMETHORPHAN HYDROBROMIDE [D6-DM]/QUINIDINE SULFATE [Q]) FOR THE TREATMENT OF AGITATION IN PATIENTS WITH DEMENTIA OF THE ALZHEIMERS TYPE No dispute reported 06/30/2026 1225335733
Principal investigator 1 Eli Lilly and Company $11,615.00 03/11/2025 Non-covered Recipient Entity
CENTRAL STATE RESEARCH
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187880903
Principal investigator 1 Novo Nordisk AS $2,152.80 02/21/2025 Non-covered Recipient Entity
CENTRAL STATES RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1213720185
Principal investigator 1 Eli Lilly and Company $1,909.25 01/31/2025 Non-covered Recipient Entity
CENTRAL STATE RESEARCH
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187878463
Principal investigator 1 Eli Lilly and Company $6,051.30 01/31/2025 Non-covered Recipient Entity
CENTRAL STATE RESEARCH
A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES, MODERATE OR SEVERE RENAL IMPAIRMENT WITH INADEQUATE GLYCEMIC CONTROL ON BASAL INSULIN WITH OR WITHOUT METFORMIN AND/OR SGLT2 INHIBITOR No dispute reported 06/30/2026 1187878913
Principal investigator 1 Novo Nordisk AS $3,777.30 01/31/2025 Non-covered Recipient Entity
CENTRAL STATES RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1213737180
Principal investigator 1 Eli Lilly and Company $2,719.29 01/22/2025 Non-covered Recipient Entity
CENTRAL STATE RESEARCH
A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH SEMAGLUTIDE ONCE WEEKLY IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN WITH OR WITHOUT SGLT2 INHIBITOR (TRANSCEND-T2D-2) No dispute reported 06/30/2026 1187878461
Principal investigator 1 Eli Lilly and Company $91,120.00 01/21/2025 Non-covered Recipient Entity
CENTRAL STATE RESEARCH
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187876635
Principal investigator 1 Eli Lilly and Company $224,268.00 01/07/2025 Non-covered Recipient Entity
CENTRAL STATE RESEARCH
A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH SEMAGLUTIDE ONCE WEEKLY IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN WITH OR WITHOUT SGLT2 INHIBITOR (TRANSCEND-T2D-2) No dispute reported 06/30/2026 1187877697